{"id":"W4417004874","doi":"10.1182/blood-2025-1016","title":"Pembrolizumab (Pembro) plus R-CHOP is efficacious as first-line therapy for primary mediastinal B-cell lymphoma (PMBL) with high rates of ctdna negativity – interim efficacy analysis of the ALLG-Pacific (NHL35) trial","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Nutrasource","funders":"","keywords":"Pembrolizumab; Interim analysis; Discontinuation; Clinical endpoint; Clinical trial; Lung cancer; Chemoimmunotherapy; Regimen; Lymphoma; Surrogate endpoint","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00219381,0.0006416274,0.001206939,0.0002562751,0.0002232101,0.0009022584,0.0005233652,0.0006224983,0.002379775],"category_scores_gemma":[0.0008847893,0.0003124966,0.001033059,0.0002930441,0.000506029,0.0006257247,0.0003757718,0.001874126,0.0004682196],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005120304,"about_ca_system_score_gemma":0.0005664331,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005335575,"about_ca_topic_score_gemma":0.001402422,"domain_scores_codex":[0.9994791,0.0003155502,0.00002685439,0.00006771628,0.00004680806,0.00006404918],"domain_scores_gemma":[0.9994092,0.0001509873,0.0001409755,0.00006107331,0.0000324979,0.0002052679],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.883736,0.00838578,0.009391283,0.00139499,0.003925498,0.0001059659,0.0001378949,0.001634795,0.01327665,0.0002225469,0.004171445,0.07361709],"study_design_scores_gemma":[0.7457812,0.191612,0.04791516,0.0002433587,0.004258566,0.0003572267,0.00008229191,0.001804403,0.002739456,0.0005359379,0.004637065,0.00003337274],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9895643,0.005371649,0.000268388,0.0004720177,0.00008739671,0.001051144,0.000974595,0.00005420027,0.002156333],"genre_scores_gemma":[0.9931487,0.001820776,0.0006891951,0.0006090431,0.0001275041,0.000929171,0.001728427,0.00001457028,0.000932592],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002379775,"threshold_uncertainty_score":0.0116021,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01613233198756853,"score_gpt":0.2823740072537165,"score_spread":0.266241675266148,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}